Literature DB >> 23478100

A novel mechanism for vascular insulin resistance in normotensive young SHRs: hypoadiponectinemia and resultant APPL1 downregulation.

Wenjuan Xing1, Wenjun Yan, Peilin Liu, Lele Ji, Youyou Li, Lu Sun, Ling Tao, Haifeng Zhang, Feng Gao.   

Abstract

Vascular insulin resistance contributes to elevated peripheral vascular resistance and subsequent hypertension. Clinical observation showed that lower plasma adiponectin concentration is significantly associated with hypertension. This study was aimed to determine whether hypoadiponectinemia induces vascular insulin resistance before systemic hypertension and the underlying mechanisms. Four-week-old young spontaneously hypertensive rats (ySHRs, normotensive) and adiponectin knockout (KO; APN(-/-)) mice were used to evaluate the role of hypoadiponectinemia in insulin-induced vasodilation of resistance vessels. ySHRs showed significant vascular insulin resistance as evidenced by the blunted vasorelaxation response to insulin in mesenteric arterioles compared with that of age-matched Wistar-Kyoto controls. Serum adiponectin and mesenteric arteriolar APPL1 (an adaptor protein that mediates adiponectin signaling) expression of ySHRs were significantly reduced. In addition, Akt and endothelial NO synthase phosphorylation and NO production in arterioles were markedly reduced, whereas extracellular signal-regulated protein kinases 1/2 (ERK1/2) phosphorylation and endothelin-1 secretion were augmented in ySHRs. APN(-/-) mice showed significantly decreased APPL1 expression and vasodilation evoked by insulin. More importantly, treatment of ySHRs in vivo with the globular domain of adiponectin for 1 week increased APPL1 expression and insulin-induced vasodilation, and restored the balance between insulin-stimulated endothelial vasodilator NO and vasoconstrictor endothelin-1. In cultured human umbilical vein endothelial cells, globular domain of adiponectin upregulated APPL1 expression. Suppression of APPL1 expression with small interfering RNA markedly blunted the globular domain of adiponectin-induced insulin sensitization as evidenced by reduced Akt/endothelial NO synthase and potentiated ERK1/2 phosphorylations. In conclusion, hypoadiponectinemia induces APPL1 downregulation in the resistance vessels, contributing to the development of vascular insulin resistance by differentially modulating the Akt/endothelial NO synthase/NO and ERK1/2/endothelin-1 pathways in vascular endothelium in normotensive ySHRs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478100     DOI: 10.1161/HYPERTENSIONAHA.111.00728

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats.

Authors:  Feng-Hao Geng; Guo-Hua Li; Xing Zhang; Peng Zhang; Ming-Qing Dong; Zhi-Jing Zhao; Yuan Zhang; Ling Dong; Feng Gao
Journal:  Br J Pharmacol       Date:  2016-04-05       Impact factor: 8.739

2.  Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses.

Authors:  Lina Zhao; Zhuo Fu; Jing Wu; Kevin W Aylor; Eugene J Barrett; Wenhong Cao; Zhenqi Liu
Journal:  J Physiol       Date:  2015-07-26       Impact factor: 5.182

3.  GRK4-mediated adiponectin receptor-1 phosphorylative desensitization as a novel mechanism of reduced renal sodium excretion in hypertension.

Authors:  Yan Zhang; Shaoxiong Wang; Hefei Huang; Andi Zeng; Yu Han; Cindy Zeng; Shuo Zheng; Hongmei Ren; Yajing Wang; Yu Huang; Pedro A Jose; Xin-Liang Ma; Chunyu Zeng; Ken Chen
Journal:  Clin Sci (Lond)       Date:  2020-09-30       Impact factor: 6.124

4.  Improvement of vascular insulin sensitivity by downregulation of GRK2 mediates exercise-induced alleviation of hypertension in spontaneously hypertensive rats.

Authors:  Wenjuan Xing; Youyou Li; Haifeng Zhang; Chunjuan Mi; Zuoxu Hou; Michael J Quon; Feng Gao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-02       Impact factor: 4.733

Review 5.  Adiponectin and insulin cross talk: the microvascular connection.

Authors:  Lina Zhao; Zhuo Fu; Zhenqi Liu
Journal:  Trends Cardiovasc Med       Date:  2014-08-07       Impact factor: 6.677

6.  Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients.

Authors:  R Dehghan; M Saidijam; N Shabab; M Yavangi; T Artimani
Journal:  J Endocrinol Invest       Date:  2016-04-13       Impact factor: 4.256

7.  C1q/TNF-related protein-9 ameliorates hypoxia-induced pulmonary hypertension by regulating secretion of endothelin-1 and nitric oxide mediated by AMPK in rats.

Authors:  Qiaoyan Jin; Hui Su; Rui Yang; Yanzhen Tan; Buying Li; Wei Yi; Qianqian Dong; Haifeng Zhang; Wenjuan Xing; Xin Sun
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

8.  Magnolol administration in normotensive young spontaneously hypertensive rats postpones the development of hypertension: role of increased PPAR gamma, reduced TRB3 and resultant alleviative vascular insulin resistance.

Authors:  Xiangyan Liang; Wenjuan Xing; Jinxiao He; Feng Fu; Wei Zhang; Feifei Su; Fange Liu; Lele Ji; Feng Gao; Hui Su; Xin Sun; Haifeng Zhang
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

9.  Rhynchophylline Ameliorates Endothelial Dysfunction via Src-PI3K/Akt-eNOS Cascade in the Cultured Intrarenal Arteries of Spontaneous Hypertensive Rats.

Authors:  Hui-Feng Hao; Li-Mei Liu; Chun-Shui Pan; Chuan-She Wang; Yuan-Sheng Gao; Jing-Yu Fan; Jing-Yan Han
Journal:  Front Physiol       Date:  2017-11-15       Impact factor: 4.566

10.  Alpha-linolenic acid exerts an endothelial protective effect against high glucose injury via PI3K/Akt pathway.

Authors:  Wei Zhang; Rong Li; Jia Li; Wenqing Wang; Ru Tie; Fei Tian; Xiangyan Liang; Wenjuan Xing; Yong He; Liang Yu; Miaomiao Xi; Siwang Wang; Qiangsun Zheng; Haifeng Zhang
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.